Clinical Trial Update: Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults [Phase 1]

View source ↗

Summary

A Phase 1 trial in healthy adults evaluated the safety and immune response of the HPIV3-EbovZ GP Ebola vaccine, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• HPIV3-EbovZ GP Ebola vaccine (HPIV3-EbovZ GP)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hemorrhagic Fever, Ebola | Phase 1 | Status: COMPLETED